New drugs in early development for treating multiple myeloma: all that glitters is not gold.
Luca BertaminiFrancesca BonelloMario BoccadoroSara BringhenPublished in: Expert opinion on investigational drugs (2020)
IMD iberdomide and the export protein inhibitor selinexor demonstrated efficacy in heavily pretreated patients who had no other therapeutic options. We expect that immunotherapy with anti-BCMA BTEs and ADCs will revolutionize the approach to treating the early stages of the disease. Data on venetoclax in t(11;14)-positive patients may pave the way for personalized therapy. Not all new agents under early clinical evaluation will be investigated in regulatory phase III trials; one of the most important challenges is to identify those that could make a difference.
Keyphrases
- phase iii
- clinical evaluation
- end stage renal disease
- multiple myeloma
- clinical trial
- ejection fraction
- open label
- chronic kidney disease
- newly diagnosed
- transcription factor
- prognostic factors
- randomized controlled trial
- peritoneal dialysis
- machine learning
- big data
- high resolution
- protein protein
- double blind
- deep learning
- artificial intelligence
- drug induced
- study protocol
- single molecule
- atomic force microscopy
- high speed